Novartis bets on gene therapy with $8.7 billion AveXis deal
ZURICH / Reuters Swiss drugmaker Novartis is moving further into gene therapy by buying AveXis for $8.7 billion, adding a rare-disease treatment that could reap billions in sales. The acquisition reflects a surge of interest in biotech deal-making as large pharmaceutical companies seek promising new assets to boost their pipelines. The $218-per-share cash deal announced on Monday represents a 72 ...
Read More »